Simon P. Tucker
Keine laufenden Positionen mehr
Karriereverlauf von Simon P. Tucker
Ehemalige bekannte Positionen von Simon P. Tucker
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Aviragen Therapeutics, Inc.
 Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
Ausbildung von Simon P. Tucker
| University of Sussex | Undergraduate Degree |
| The University of Reading | Doctorate Degree |
Statistik
International
| Vereinigtes Königreich | 3 |
| Vereinigte Staaten | 2 |
Operativ
| Chief Tech/Sci/R&D Officer | 1 |
| Undergraduate Degree | 1 |
| Doctorate Degree | 1 |
Sektoral
| Consumer Services | 3 |
| Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | Health Technology |
- Börse
- Insiders
- Simon P. Tucker
- Erfahrung
